Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dato-DXd master protocol in advanced/metastatic solid tumors
jRCT2031220404Phase 2Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Feb 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label trial of datopotamab deruxtecan in endometrial cancer (EC), gastric cancer (GC), prostate cancer (PCa) and 4 more (14 arms), sponsored by Daiichi Sankyo Co., Ltd. Primary endpoints: Objective response rate, Adverse events and serious adverse events and 2 more. Started Feb 2023; status: recruiting.
02
Drugs
datopotamab deruxtecan
03
Conditions
endometrial cancer (EC)gastric cancer (GC)prostate cancer (PCa)ovarian cancercolorectal cancer (CRC)
Beyond the preview
Go deeper on jRCT2031220404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220404.